HERG1 channel agonists and cardiac arrhythmia

Current Opinion in Pharmacology

Volumn 15, Issue 1, 2014, Pages 22-27

  Sanguinetti, Michael C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (6 METHOXY 4 QUINOLINYL) 3 OXOPROPYL] 1 [3 (2,3,5 TRIFLUOROPHENYL) 2 PROPYNYL] 3 PIPERIDINECARBOXYLIC ACID; A 935142; AMIODARONE; ANTIARRHYTHMIC AGENT; GINSENOSIDE RG 3; HERG1 CHANNEL AGONIST; ICA 105574; KB 130015; MALLOTOXIN; NS 1643; NS 3623; PD 118057; PD 307243; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG1; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CHANNEL GATING; DRUG STRUCTURE; DRUG TARGETING; GENE INACTIVATION; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HERG1 GENE; HUMAN; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SUDDEN DEATH;

ACTION POTENTIALS; ARRHYTHMIAS, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ION CHANNEL GATING;

EID: 84889831052     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.11.006     Document Type: Review

References (48)

1. I. Goldenberg, A.J. Moss, D.R. Peterson, S. McNitt, W. Zareba, M.L. Andrews, J.L. Robinson, E.H. Locati, M.J. Ackerman, J. Benhorin, and E.S. Kaufman Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome Circulation 117 2008 2184 2191
2. C. Jons, A.J. Moss, I. Goldenberg, J. Liu, S. McNitt, W. Zareba, M. Qi, and J.L. Robinson Risk of fatal arrhythmic events in long QT syndrome patients after syncope J Am Coll Cardiol 55 2010 783 788
3. R.R. Shah Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives Br J Pharmacol 159 2010 58 69
4. + channel Mol Pharmacol 67 2005 827 836 (Pubitemid 40365330)
5. D. Noble, and R.W. Tsien Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres J Physiol 200 1969 205 231
6. + current: differential sensitivity to block by class III antiarrhythmic agents J Gen Physiol 96 1990 195 215 (Pubitemid 20227082)
7. Kr potassium channel Cell 81 1995 299 307
8. M. Trudeau, J.W. Warmke, B. Ganetzky, and G.A. Robertson HERG, A human inward rectifier in the voltage-gated potassium channel family Science 269 1995 92 95
9. M.E. Curran, I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, and M.T. Keating A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 80 1995 795 803
10. + channels: structure, function, and clinical significance Physiol Rev 92 2012 1393 1478
11. M.T. Keating, and M.C. Sanguinetti Molecular and cellular mechanisms of cardiac arrhythmias Cell 104 2001 569 580 (Pubitemid 32201951)
12. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome Cardiovasc Res 67 2005 498 509 (Pubitemid 41019557)
13. Y. Sun, X.Q. Quan, S. Fromme, R.H. Cox, P. Zhang, L. Zhang, D. Guo, J. Guo, C. Patel, P.R. Kowey, and G.X. Yan A novel mutation in the KCNH2 gene associated with short QT syndrome J Mol Cell Cardiol 50 2011 433 441
14. M.C. Sanguinetti hERG1 channelopathies Pflugers Archiv Eur J Physiol 460 2010 265 276
15. + channel. A model for bad behavior J Med Chem 46 2003 2017 2022 (Pubitemid 36583481)
16. B. Fermini, and A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development Nat Rev Drug Discov 2 2003 439 447 (Pubitemid 37361725)
17. + channel deactivation through Ser631 residue interaction Eur J Pharmacol 663 2011 59 67
18. + channel currents through interacting with the K318 and V319 residues: a role of KCNE1 subunit Eur J Pharmacol 637 2010 138 147
19. A.C. Gerlach, S.J. Stoehr, and N.A. Castle Pharmacological removal of human ether-A-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574) Mol Pharmacol 77 2009 58 68
20. M. Asayama, J. Kurokawa, K. Shirakawa, H. Okuyama, T. Kagawa, J. Okada, S. Sugiura, T. Hisada, and T. Furukawa Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts J Pharmacol Sci 121 2013 1 8
21. J. Meng, C. Shi, L. Li, Y. Du, and Y. Xu Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization Eur J Pharmacol 718 2013 87 97
22. H. Zeng, I.M. Lozinskaya, Z. Lin, R.N. Willette, D.P. Brooks, and X. Xu Mallotoxin is a novel human ether-A-go-go-related gene (hERG) potassium channel activator J Pharmacol Exp Ther 319 2006 957 962
23. G. Gessner, R. Macianskiene, J.G. Starkus, R. Schonherr, and S.H. Heinemann The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism Eur J Pharmacol 632 2010 52 59
24. J. Zhou, C.E. Augelli-Szafran, J.A. Bradley, X. Chen, B.J. Koci, W.A. Volberg, Z. Sun, and J.S. Cordes Novel potent human ether-A-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity Mol Pharmacol 68 2005 876 884 (Pubitemid 41206044)
25. + conductance Proc Natl Acad Sci USA 106 2009 20075 20080
26. Z. Su, J. Limberis, A. Souers, P. Kym, A. Mikhail, K. Houseman, G. Diaz, X. Liu, R.L. Martin, B.F. Cox, and G.A. Gintant Electrophysiologic characterization of a novel hERG channel activator Biochem Pharmacol 77 2009 1383 1390
27. E. Gordon, I.M. Lozinskaya, Z. Lin, S.F. Semus, F.E. Blaney, R.N. Willette, and X. Xu 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5- ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-A-go-go-related gene potassium channels Mol Pharmacol 73 2008 639 651 (Pubitemid 351397869)
28. X. Xu, M. Recanatini, M. Roberti, and G.N. Tseng Probing the binding sites and mechanisms of action of two human ether-A-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243) Mol Pharmacol 73 2008 1709 1721 (Pubitemid 351724359)
29. + channel isoforms by NS1643 in human embryonic kidney 293 and Chinese hamster ovary cells Mol Pharmacol 80 2011 930 942
30. O. Casis, S.P. Olesen, and M.C. Sanguinetti Mechanism of action of a novel human ether-A-go-go-related gene channel activator Mol Pharmacol 69 2006 658 665 (Pubitemid 43121963)
31. P. Elmedyb, S.P. Olesen, and M. Grunnet Activation of ERG2 potassium channels by the diphenylurea NS1643 Neuropharmacology 53 2007 283 294 (Pubitemid 47187454)
32. A. Bilet, and C.K. Bauer Effects of the small molecule HERG activator NS1643 on Kv11.3 channels PLoS ONE 7 2012 e50886
33. Kr agonist NS3623 on cardiac electrophysiology of the guinea pig J Cardiovasc Pharmacol 52 2008 35 41
34. Kr impairs conduction in Guinea pig hearts J Cardiovasc Electrophysiol 21 2010 823 829
35. X. Liu, J.T. Limberis, Z. Su, K. Houseman, G.J. Diaz, G.A. Gintant, B.F. Cox, and R.L. Martin Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers Life Sci 90 2012 607 611
36. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proc Natl Acad Sci USA 97 2000 12329 12333
37. J.P. Lees-Miller, Y. Duan, G.Q. Teng, and H.J. Duff Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites Mol Pharmacol 57 2000 367 374 (Pubitemid 30084514)
38. M. Perry, F.B. Sachse, and M.C. Sanguinetti Structural basis of action for a human ether-A-go-go-related gene 1 potassium channel activator Proc Natl Acad Sci USA 104 2007 13827 13832 (Pubitemid 350003405)
39. + channel activation by NS1643 Mol Pharmacol 79 2011 1 9
40. V. Garg, A. Stary-Weinzinger, F. Sachse, and M.C. Sanguinetti Molecular determinants for activation of human ether-A-go-go-related gene 1 potassium channels by 3-nitro-N-(4-phenoxyphenyl) benzamide Mol Pharmacol 80 2011 630 637
41. + channel inactivation: molecular determinants of amplification by mutations and a small molecule J Gen Physiol 140 2012 307 324
42. V. Garg, A. Stary-Weinzinger, and M.C. Sanguinetti ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels Mol Pharmacol 83 2013 805 813
43. E. Nof, A. Burashnikov, and C. Antzelevitch Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy Heart Rhythm 7 2010 251 257
44. C. Patel, and C. Antzelevitch Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome Heart Rhythm 5 2008 585 590
45. T.G. Diness, Y.H. Yeh, X.Y. Qi, D. Chartier, Y. Tsuji, R.S. Hansen, S.P. Olesen, M. Grunnet, and S. Nattel Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome Cardiovasc Res 79 2008 61 69 (Pubitemid 351881940)
46. B.H. Bentzen, S. Bahrke, K. Wu, A.P. Larsen, K.E. Odening, G. Franke, K. Storm vans Gravesande, J. Biermann, X. Peng, G. Koren, and M. Zehender Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits J Cardiovasc Pharmacol 57 2011 223 230
47. A.C. Gerlach, S.J. Stoehr, and N.A. Castle Pharmacological removal of human ether-A-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574) Mol Pharmacol 77 2010 58 68
48. R.S. Hansen, T.G. Diness, T. Christ, E. Wettwer, U. Ravens, S.P. Olesen, and M. Grunnet Biophysical characterization of the new human ether-A-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5- yl)-phenyl)-N′-(3′-trifluoromethylphenyl)urea] Mol Pharmacol 70 2006 1319 1329 (Pubitemid 44435984)